Clinical Trial Update: A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing wakefulness promoting effects, safety, tolerability, and pharmacokinetics of LML134 in shift work disorder was terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Circadian Rhythm Disorders

Drugs mentioned

• LML134

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Circadian Rhythm Disorders | Phase 2 | Status: TERMINATED | Results posted: 2019-09-24